CareDx said it will commercialize Cibiltech’s Predigraft, in return for taking a minority stake in the French AI-based medical technology developer, the companies said today, through a collaboration whose value was not disclosed.
Predigraft is an AI-based data analysis tool designed to predict risk of allograft rejection and transplant loss. Predigraft was developed from Cibiltech’s “iBox” proprietary software algorithm based on outcomes data from tens of thousands of transplant patients.
Based in Brisbane, CA, CareDx is a molecular diagnostics developer focused on commercializing what it deems high-value diagnostic solutions for transplant patients. Last week, CareDx said it agreed to acquire Omaha, NE-based OTTR Chronic Care Solutions, a provider of organ transplant patient tracking software, for $16 million cash.
“CareDx has taken another step towards bringing big data solutions to transplant patients,” said Peter Maag, CEO of CareDx. “With OTTR providing data infrastructure and with iBox providing prognostic information, we are beginning to assemble new and important solutions for caregivers that are based on artificial intelligence.”
Cibiltech’s founding partner Alexandre Loupy, MD, PhD, is director of the transplantation-focused clinical center Paris Transplant Group and inventor of iBox, an integrated diagnostic system designed to enable users to:
- Make correlations with conventional features of rejection and transplant pathology;
- Improve diagnostic accuracy;
- Provide mechanistic insights into exploring new pathways and operational biological processes involved in transplant rejection.
“We are delighted to collaborate with CareDx as it is a very promising step to bring years of work on artificial intelligence from the Paris Transplant Group to transplant patients. Our technology has been selected by numerous peer reviewed publications, and we believe that the team at CareDx is a great partner to make this available to the field of transplantation,” Loupy said in a statement.
Under the companies’ agreement, CareDx holds exclusive rights to commercialize Predigraft in the U.S., and becomes a minority equity owner of CibilTech. The companies also agreed to collaborate to advance the development of artificial intelligence in transplant care.
CareDx and Cibiltech will share demonstrations of iBox at the American Transplant Congress, set for June 1-4 in Boston.
“I see incredible value in using prognostic data alongside a measure of organ injury from non-invasive biomarkers such as AlloSure,” added Gaurav Gupta, MD, of Virginia Commonwealth University. AlloSure is CareDx’s non-invasive test designed to assess organ health by directly measuring allograft injury.
“This can give me insights that shape the care I give to my transplant patients,” Gupta added.